Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment of patients with advanced tumors. However, little is known about their efficacy and safety in adjuvant settings after the resection of solid tumors. METHODS: We performed a meta-analysis on the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yao, Wei, Jiayan, Weng, Yiming, Feng, Jia, Xu, Zexi, Wang, Peiwei, Cui, Xue, Chen, Xinyi, Wang, Jinsong, Peng, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913885/
https://www.ncbi.nlm.nih.gov/pubmed/35280727
http://dx.doi.org/10.3389/fonc.2022.732814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913885/
https://www.ncbi.nlm.nih.gov/pubmed/35280727
http://dx.doi.org/10.3389/fonc.2022.732814

Ejemplares similares